This article is more than 5 years old. Information may no longer be current.

Bionic eye system gains financial support in France

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The French Ministry of Health has approved financial support for a bionic eye treatment, according to a Second Sight Medical Products press release.

The approval of the Argus II Retinal Prosthesis System (Second Sight) comes after the March 18, 2014, decision to add the Argus II system to the Forfait Innovation program, which introduces therapies to benefit patients with retinitis pigmentosa in France, according to the release.

On Sept. 1, three French hospitals will begin the program by administering the treatment to 36 patients with severe to total sight loss due to retinitis pigmentosa.

Under the financial support approval, the French government will cover the cost of this first wave of treatment through the Forfait Innovation program, according to the release.

The Argus II was granted a CE mark in 2011 and U.S. Food and Drug Administration approval in 2013.